| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7851482 | ENDO PHARMS | Method for making analgesics |
Jul, 2029
(5 years from now) | |
| US8871779 | ENDO PHARMS | Process for preparing morphinan-6-one products with low levels of α,β-unsaturated ketone compounds |
Nov, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5958456 | ENDO PHARMS | Controlled release formulation (albuterol) |
Sep, 2013
(10 years ago) | |
| US5662933 | ENDO PHARMS | Controlled release formulation (albuterol) |
Sep, 2013
(10 years ago) | |
| US8309122 | ENDO PHARMS | Oxymorphone controlled release formulations |
Feb, 2023
(1 year, 2 months ago) | |
| US8309112 | ENDO PHARMS | Coatings for implantable medical devices comprising hydrophilic substances and methods for fabricating the same |
Feb, 2023
(1 year, 2 months ago) | |
| US8329216 | ENDO PHARMS | Oxymorphone controlled release formulations |
Feb, 2023
(1 year, 2 months ago) | |
| US7276250 | ENDO PHARMS | Sustained release formulations of oxymorphone |
Feb, 2023
(1 year, 2 months ago) | |
| US8309060 | ENDO PHARMS | Abuse-proofed dosage form |
Nov, 2023
(5 months ago) | |
| US8075872 | ENDO PHARMS | Abuse-proofed dosage form |
Nov, 2023
(5 months ago) | |
| US8114383 | ENDO PHARMS | Abuse-proofed dosage form |
Aug, 2024
(3 months from now) | |
| US8192722 | ENDO PHARMS | Abuse-proof dosage form |
Sep, 2025
(1 year, 4 months from now) | |
| US8808737 | ENDO PHARMS | Method of treating pain utilizing controlled release oxymorphone pharmaceutical compositions and instruction on dosing for renal impairment |
Jun, 2027
(3 years from now) | |
Opana Er is owned by Endo Pharms.
Opana Er contains Oxymorphone Hydrochloride.
Opana Er has a total of 13 drug patents out of which 8 drug patents have expired.
Expired drug patents of Opana Er are:
- US5958456
- US5662933
- US8309122
- US8309112
- US8329216
- US7276250
- US8309060
- US8075872
Opana Er was authorised for market use on 22 June, 2006.
Opana Er is available in tablet, extended release;oral dosage forms.
Opana Er can be used as relief of moderate to severe pain, dose modification for renal impairment.
The generics of Opana Er are possible to be released after 22 November, 2029.
Drugs and Companies using OXYMORPHONE HYDROCHLORIDE ingredient
Market Authorisation Date: 22 June, 2006
Treatment: Relief of moderate to severe pain; Dose modification for renal impairment
Dosage: TABLET, EXTENDED RELEASE;ORAL
OPANA ER family patents
